行情

EVFM

EVFM

Evofem
NASDAQ

实时行情|Nasdaq Last Sale

6.33
+0.03
+0.48%
盘后: 6.33 0 0.00% 16:00 12/11 EST
开盘
6.50
昨收
6.30
最高
6.69
最低
6.24
成交量
5.68万
成交额
--
52周最高
7.50
52周最低
3.160
市值
1.12亿
市盈率(TTM)
-2.5171
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

EVFM 新闻

  • H.C. Wainwright Reiterates Buy on Evofem Biosciences, Raises Price Target to $11
  • Benzinga.18小时前
  • Evofem Biosciences (EVFM) Presents At Piper Jaffray Healthcare Conference - Slideshow
  • Seeking Alpha - Article.6天前
  • PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®
  • PR Newswire.12/03 14:00
  • The Daily Biotech Pulse: Astellas To Buy Audentes For $3B, Applied Genetics Chief Medical Officer Quits, Axsome Aces Midstage Trial
  • Benzinga.12/03 12:59

更多

所属板块

制药
+0.17%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

EVFM 简况

Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.
展开

Webull提供Evofem Biosciences Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。